**SUPPLEMETARY MATERIAL**

**Efficacy and safety of combined therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis**

Jin-Young Huh, Jae Ha Lee, Jin Woo Song

Supplementary Table 1. Serious adverse events that occurred after the start of combination therapy

|  |  |
| --- | --- |
| Characteristics | Total |
| Total patients | 45 |
| Patients who experienced SAEs | 14 (31.1) |
| Acute exacerbation | 3 (6.7) |
| Pneumonia | 3 (6.7) |
| Pneumomediastinum | 1 (2.2) |
| Death | 6 (13.3) |
| Causes of death |  |
| Acute exacerbation | 3 (6.7) |
| Unknown | 2 (4.5) |
| Septic shock | 1 (2.2) |

Data are presented as the number (%) of patients. SAE, serious adverse events

Supplementary Table 2. Characteristics of the IPF cohort included in the matched analysis

|  |  |
| --- | --- |
| Characteristics | Total |
| Number of patients | 1,360 |
| Age, years | 66.4 ± 8.0 |
| Sex, male | 1105 (81.3) |
| Body mass index, kg/m2 | 24.3 ± 3.1 |
| Pulmonary function test |  |
| FVC, % of predicted | 69.9 ± 16.1 |
| TLC, % of predicted | 70.5 ± 14.8 |
| DLCO, % of predicted | 56.7 ± 17.8 |
| Follow-up duration, months | 27.3 (12.5–55.3) |

Data are presented as the mean ± standard deviation or number (%) of patients or median (interquartile range).

*Abbreviations*: IPF, idiopathic pulmonary fibrosis; FVC, forced vital capacity; TLC, total lung capacity; DLCO, diffusing capacity of the lungs for carbon monoxide

Supplementary Table 3. Baseline characteristics of patients from the combination therapy and matched monotherapy groups

|  |  |  |  |
| --- | --- | --- | --- |
| Adverse events | Combination Therapy | Monotherapy | *p* value |
| Number of patients | 32 | 64 |  |
| Age | 68.5 ± 6.0 | 68.2 ± 5.9 | 0.866 |
| Male | 30 (93.8) | 60 (93.8) | >0.999 |
| Body mass index, kg/m2 | 25.0 ± 3.2 | 24.7 ± 2.4 | 0.710 |
| Pulmonary function test |  |  |  |
| FVC, % predicted | 60.8 ± 11.3 | 60.3 ± 11.4 | 0.848 |
| DLCO, % predicted | 47.5 ± 10.1 | 44.4 ± 10.5 | 0.179 |
| Median time from IPF diagnosis, days | 859.0 (460.5–1432.0) | 135.5 (21.0–768.5) | <0.005 |

Data are presented as the mean ± standard deviation or number (%) of patients.

*Abbreviations*: FVC, forced vital capacity; DLCO, diffusing capacity of the lungs for carbon monoxide

Supplementary Figure 1. Flow chart of patients included in the study



*Abbreviations*: IPF, idiopathic pulmonary fibrosis; AMC, Asan Medical Center

Supplementary Figure 2. Comparison of clinical outcomes between patients from the combination therapy and matched monotherapy groups

도표, 스케치, 기술 도면, 평면도이(가) 표시된 사진

자동 생성된 설명

(A) Changes in FVC, mL; (B) changes in DLCO, mL CO/min/mmHg; (C) changes in 6MWD, m

*Abbreviations*: FVC, forced vital capacity; DLCO, diffusing capacity of the lungs for carbon monoxide; 6MWD, 6-min walking distance